AgomAb Therapeutics NV (AGMB)
| Market Cap | 410.24M |
| Revenue (ttm) | n/a |
| Net Income | -93.23M |
| EPS | -4.51 |
| Shares Out | 49.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,912 |
| Open | 8.56 |
| Previous Close | 8.69 |
| Day's Range | 8.15 - 8.86 |
| 52-Week Range | 7.97 - 17.82 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.67 (+352.22%) |
| Est. Earnings | Nov 14, 2026 |
About AGMB
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 cli... [Read more]
Analyst Summary
According to 7 analysts, the average rating for AGMB stock is "Strong Buy." The 12-month stock price target is $37.67, which is an increase of 352.22% from the latest price.
News
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab announced that the first patient has been dosed in NOV-ERA, the Company's Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.
AgomAb Therapeutics NV Transcript: Study result
In the 49-patient STENOVA open-label extension, ontunisertib maintained favorable safety and gut-restricted PK through up to 60 weeks. Exploratory findings included a 3% event rate and 97% clinical remission at week 48, with efficacy interpretation limited by the uncontrolled design.
AgomAb Therapeutics NV Press release: Study result
AgomAb Therapeutics NV issued a press release on October 1, 2026, disclosing material business information to investors.
AgomAb Therapeutics NV Slides: Study result
AgomAb Therapeutics NV has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Agomab’s ontunisertib shows positive results in Crohn’s Disease study
Agomab (AGMB) announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with Fibrostenosing Crohn’s disease or FSCD, a severe manifestatio...
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn's disease (FSCD) patients -- -- Low annualized FSCD-related event ...
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high expo...
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab announced shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting
Agomab to Participate in Upcoming Investor Conferences
Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the ma...
Agomab initiated with an Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi initiated coverage of Agomab (AGMB) with an Overweight rating and $60 price target The company’s ontunisertib is “poised for success” in fibrostenotic Crohn’s dise...
Agomab initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Agomab (AGMB) with an Overweight rating. Agomab’s two-asset pipeline offers multiple 2H26 value inflection points, with ontunisertib’...
Agomab initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Agomab (AGMB) with an Overweight rating.
AgomAb Therapeutics NV Earnings release: Q2 2026
AgomAb Therapeutics NV released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Agomab initiated with a Buy at B. Riley
B. Riley initiated coverage of Agomab (AGMB) with a Buy rating and $34 price target The firm sees lead drug ontunisertib as a first mover in fibrostenotic Crohn’s, which it…
Agomab Therapeutics NV trading resumes
16:00 EDT Agomab (AGMB) Therapeutics NV trading resumes
Agomab Therapeutics NV trading halted, volatility trading pause
15:51 EDT Agomab (AGMB) Therapeutics NV trading halted, volatility trading pause
Agomab announces NOV-ERA study design
Agomab (AGMB) announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted small molecule inhibitor of ALK5 for the potential tr...
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation...
Agomab initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio initiated coverage of Agomab (AGMB) with a Buy rating and $35 price target The firm says both of Agomab’s clinical programs are engineered to achieve…
Agomab Announces Results of Annual General Meeting
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual G...
Agomab to Participate in Upcoming Conferences
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the managem...
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- P...
AgomAb Therapeutics NV Earnings release: Q4 2025
AgomAb Therapeutics NV released its Q4 2025 earnings on April 23, 2026, summarizing the period's financial results.
AgomAb Therapeutics NV Annual report: Q4 2025
AgomAb Therapeutics NV has published its Q4 2025 annual report on April 23, 2026.
Agomab receives U.S. patent for AGMB-447
Agomab (AGMB) announced that the United States Patent and Trademark Office, or USPTO, has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is…